References
- Knutson D, Greenberg G, Cronau H. Management of Crohn’s disease – a practical approach. Am Fam Phys 2003;68:707–14
- McCay DM. Intestinal inflammation and the gut microflora. Can J Gastroenterol 1999;13:509–16
- Cangemi JR. The role of antibiotics in Crohn’s disease. Dig Dis 1999;17:1–5
- Sartor RB. Review article: role of the enteric microflora in the pathogenesis of intestinal inflammation and arthritis. Aliment Pharmacol Ther 1997;11(Suppl 3):17–23
- Isaacs KL, Sartor RB. Antibiotics in IBD. Treatment of inflammatory bowel disease with antibiotics. Gastroenterol Clin North Am 2004;33:335–45
- Hendrickson BA, Gokhale R, Cho JH. Clinical aspects and patho-physiology of inflammatory bowel disease. Clin Microbiol Rev 2002;15:79–94
- Mow WS, Vasiliauskas EA, Lin YC, et al. Association of antibody responses to microbial antigens and complications of small bowel Crohn’s disease. Gastroenterology 2004;126:414–24
- Podolsky DK. Inflammatory bowel disease. New Engl J Med 2002;347:417–29
- Sutherland L, Singleton J, Sessions J, et al. Double-blind placebo-controlled trial of metronidazole in Crohn’s disease. Gut 1991;32:1071–5
- Jakobovits J, Schuster MM. Metronidazole therapy for Crohn’s disease and associated fistulae. Am J Gastroenterol 1984;79:533–40
- Brandt LJ, Bernstein LH, Boley SJ, et al. Metronidazole therapy for perineal Crohn’s disease: a follow-up study. Gastroenterology 1982;83:383–7
- Prantera C, Zannoni F, Scribano ML, et al. An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am J Gastroenterol 1996;91:328–32
- Arnold GL, Beaves MR, Pryjdun VO, et al. Preliminary study of ciprofloxacin in active Crohn’s disease. Inflamm Bowel Dis 2002;8:10–5
- Goodgame RW, Kimball K, Ike AE, et al. Randomized controlled trial of clarithromycin and ethambutol in the treatment of Crohn’s disease. Aliment Pharmacol Ther 2001;15:1861–6
- Shafran I, Kugler L, El-Zaatari FA, et al. Open clinical trial of rifabutin and clarithromycin therapy in Crohn’s disease. Dig Liver Dis 2002;34:22–8
- Chamberlin W, Hulten K, Graham DY. Antibiotics as primary therapy for Crohn’s disease. Drugs Today 2000;36:667–78
- Sandborn WJ, Feagan BJ. Review article: mild to moderate Crohn’s disease – defining the basis for a new treatment algorithm. Aliment Pharmacol Ther 2003;18:263–77
- Gillis JC, Brogden RN. Rifaximin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential in conditions mediated by gastrointestinal bacteria. Drugs 1995;49:467–84
- Steffen R. The emerging role of nonabsorbable oral antibiotic therapy in the management of travelers’ diarrhea. Adv Stud Med 2003;3:S951–S958
- Steffen R, Sack DA, Riopel L, et al. Therapy of travelers’ diarrhea with rifaximin on various continents. Am J Gastro 2003;98:1073–8
- DuPont H, Ericsson CD, Mathewson JJ, et al. Rifaximin: a nonabsorbed antimicrobial in the therapy of travelers’ diarrhea. Digestion 1998;59:708–14
- DuPont HL, Jiang Z-D, Ericsson CD, et al. Rifaximin versus ciprofloxacin for the treatment of traveler’s diarrhea: a randomized, double-blind clinical trial. Clin Infect Dis 2001;33:1807–15
- Fiorucci S, Distrutti E, Mencarelli A, et al. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propia monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 2002;66:246–56
- Best WR, Becktel JM, Singleton JW, et al. Development of a Crohn’s Disease Activity Index: national cooperative of Crohn’s disease study. Gastroenterology 1976;70:439–44
- Mannon PJ, Fuss IJ, Mayer L, et al. Anti-interleukin-12 antibody for active Crohn’s disease. New Engl J Med 2004;351:2069–79
- Sandborn WJ, Hanauer S, Loftus Jr EV, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn’s disease. Am J Gastroenterol 2004;99:1984–9